Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on November 4, 2020. The report addresses a regulatory notice received from the Nasdaq Stock Market LLC regarding the company's compliance with continued listing standards.
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the receipt of a deficiency notice from Nasdaq. The Company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). This is a change in regulatory standing rather than a change in operational financial performance.
Outlook, Risks, and Contingencies
- Grace Period: The Company has been granted an initial 180-calendar-day grace period to regain compliance, ending on May 3, 2021.
- Compliance Requirement: To cure the deficiency, the common stock must close at or above $1.00 per share for at least 10 consecutive business days within the grace period.
- Extension Possibility: If compliance is not met by May 3, 2021, the Company may be eligible for an additional 180-day grace period. Qualification requires meeting all other initial listing standards (excluding bid price) and potentially effecting a reverse stock split.
- Delisting Risk: If the Company fails to cure the deficiency or is ineligible for an extension, Nasdaq will issue a notice of delisting.
- Current Status: The stock remains listed and traded on The Nasdaq Capital Market pending the outcome of the grace period.
Investor Verification Checklist
- Monitor the daily closing bid price of COCP to track progress toward the $1.00 threshold.
- Verify if the Company announces a reverse stock split to address the bid price deficiency.
- Check for subsequent 8-K filings regarding the status of the grace period or any extension requests.
- Review the Company's most recent 10-K or 10-Q for underlying financial health, as this 8-K contains no financial data.